Mark J. Ratain to Drugs, Investigational
This is a "connection" page, showing publications Mark J. Ratain has written about Drugs, Investigational.
Connection Strength
1.799
-
Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res. 2015 Nov 15; 21(22):5057-63.
Score: 0.509
-
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res. 2014 Aug 15; 20(16):4210-7.
Score: 0.467
-
Drug combinations: dangerous liaisons or great expectations? Ann Oncol. 1999 Apr; 10(4):375-6.
Score: 0.161
-
The Molecular Profiling Lottery: More Accuracy, Less Precision, and No Cost. Clin Cancer Res. 2019 02 15; 25(4):1136-1138.
Score: 0.157
-
New phase I trial methodology. Semin Oncol. 1997 Apr; 24(2):253-61.
Score: 0.140
-
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res. 2010 Mar 15; 16(6):1764-9.
Score: 0.086
-
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res. 2010 Mar 15; 16(6):1745-55.
Score: 0.086
-
Inside information: Financial conflicts of interest for research subjects in early phase clinical trials. J Natl Cancer Inst. 2004 May 05; 96(9):656-61.
Score: 0.057
-
Anticancer drug discovery and development throughout the world. J Clin Oncol. 2002 Sep 15; 20(18 Suppl):47S-59S.
Score: 0.051
-
Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients. IRB. 2000 May-Jun; 22(3):6-14.
Score: 0.043
-
Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst. 1999 Aug 04; 91(15):1281-7.
Score: 0.041